http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Arrowhead Pharmaceuticals to Webcast Fiscal 2017 Second Quarter Results
-
Arrowhead Research (ARWR) Presents ARC-AAT Clinical Data at ILC
-
Arrowhead Pharmaceuticals Presents ARC-AAT Clinical Data at The International Liver Congress™
-
Arrowhead Presents ARC-520 and ARC-521 Clinical Data at The International Liver Congress™
-
Arrowhead Research (ARWR) Announces Presentations at ILC
-
Arrowhead Pharmaceuticals Announces Presentations at The International Liver Congress™
-
Arrowhead Research (ARWR) Adopts Stockholder Rights Agreement
-
Arrowhead Pharmaceuticals Adopts Stockholder Rights Agreement
-
Arrowhead Reports Fiscal 2017 First Quarter Results
-
Arrowhead Pharmaceuticals to Webcast Fiscal 2017 First Quarter Results
-
Arrowhead Research (ARWR) Says It's Had No Discussion on Potential Transaction with Silence
-
Arrowhead Provides Response to New Minority Shareholder Announcement
-
Arrowhead Reports Fiscal 2016 Year End Results
-
Arrowhead Pharmaceuticals to Webcast Fiscal 2016 Year End Results
-
Arrowhead Research (ARWR) to Discontinue ARC-520, ARC-521, and ARC-AAT Development; Will Cut Workforce
-
Arrowhead Pharmaceuticals Focuses Resources on Subcutaneous and Extra-Hepatic RNAi Therapeutics
-
Arrowhead Research (ARWR) Reports Closing of License and Collaboration Agreement with Amgen (AMGN) on RNAi ARC-LPA Program
-
Arrowhead Pharmaceuticals Announces Closing of License and Collaboration Agreement with Amgen
-
Arrowhead Research (ARWR) Announces Presentations of ARC-LPA, ARC-F12 Data at AHA Scientific Sessions 2016
-
Arrowhead Pharmaceuticals Presents New Data on ARC-F12 and ARC-LPA Using DPCsqTM Subcutaneous RNAi Delivery Vehicle
-
Arrowhead Pharmaceuticals Presents New Data on ARC-AAT
-
Arrowhead Research (ARWR) Announces FDA Clinical Hold Placed on Heparc-2004 Study
-
Arrowhead Pharmaceuticals Provides Update on Heparc-2004 Study
-
Arrowhead Pharmaceuticals to Present at Upcoming Conferences
-
Arrowhead Pharmaceuticals to Present Data on ARC-AAT at The Liver Meeting®
-
Pre-Open Stock Movers 10/06: (ALQA) (SCYX) (ZUMZ) Higher; (ALNY) (TWTR) (MDCO) Lower (more...)
-
Arrowhead Research (ARWR),Spring Bank Pharma (SBPH) Enter Collaboration on Chronic HBV Treatments Development
-
Arrowhead and Spring Bank Announce Clinical Collaboration for ARC-520 and SB 9200 in Chronic Hepatitis B
-
Amgen (AMGN), Arrowhead Pharma (ARWR) Enter Two Cardiovascular-Focused License, Collaboration Agreements
-
Amgen (AMGN), Arrowhead Pharmaceuticals (ARWR) Enter Collaborations on Two Cardiovascular Therapies
-
Amgen And Arrowhead Pharmaceuticals Announce Two Cardiovascular Collaborations
-
Arrowhead Pharmaceuticals Doses First Patient with Hepatitis B in Multiple Ascending Dose Portion of Phase 1/2 Study of ARC-521
-
Arrowhead Research (ARWR) Initiated Phase 2 Clinical Study of ARC-AAT in AATD
-
Arrowhead Pharmaceuticals Initiates Phase 2 Study of ARC-AAT
-
Arrowhead Pharmaceuticals to Present at Upcoming September Conferences
-
Arrowhead Pharmaceuticals Closes $45 Million Private Offering
-
Arrowhead Reports Fiscal 2016 Third Quarter Results
-
Arrowhead Research (ARWR) Prices $45M Private Stock Offering at $5.90/Share
-
Arrowhead Pharmaceuticals Prices $45 Million Private Offering
-
Arrowhead Pharmaceuticals to Webcast Fiscal 2016 Third Quarter Results
-
Arrowhead Pharmaceuticals to Present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference
-
Arrowhead Research (ARWR) Begins Phase 1/2 Single and Multiple Dose Study of HBV Candidate ARC-521
-
Arrowhead Pharmaceuticals Initiates Phase 1/2 Single and Multiple Dose Study of Hepatitis B Candidate ARC-521
-
Arrowhead Pharmaceuticals to Present at the Jefferies 2016 Healthcare Conference
-
Arrowhead Reports Fiscal 2016 Second Quarter Results
-
Arrowhead Pharmaceuticals’ Preclinical Candidate ARC-LPA Achieves 98% Knockdown and Long Duration of Effect after Subcutaneous Administration
-
Arrowhead Pharmaceuticals to Webcast Fiscal 2016 Second Quarter Results
-
Arrowhead Pharmaceuticals to Present at Upcoming May Conferences
-
Arrowhead Research (ARWR) Files for Clearance to Begin Phase 1/2 Study of ARC-521
-
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1/2 Study of ARC-521

